to evaluate efficacy of combination of Aspirin and atorvastatin in comparison with atorvastatin alone for improvement of liver fibrosis and function among cases of cryptogenic cirrhosis.

in this randomized double blind clinical trail, 40 patients with cryptogenic liver cirrhosis randomly allocated to receive either atorvastatin plus ASA or atorvastatin alone for a six months period and compared for viewpoint of liver function and stiffness thereafter.

Overall 33 cases with cryptogenic cirrhosis included. After randomization, 16 participants in group A and 17 in group B evaluated for final analysis. Average age of patients in group A & B were 50.3± 11.2 and 47.9± 10.6 and average BMI of participants in 2 groups were 30.7± 4.2 and 30.8± 3.1 respectively. 12 patients in group A (75%) and 14 cases in group B (82%) were male. The baseline demographic characters of 2 groups were similar. After 6 months of intervention, the decrease in average ALT level was not significant in group A (atorvastatin + ASA) while this item in group B (atorvastatin + placebo) was meaningful (P=0.009). Average Child score of participants in both groups improved significantly (P= 0.0001 & 0.002 respectively) and also the liver stiffness measurement by Fibroscan proved a significant decrease (group A; P<0.001 & group B; P=0.007) . Despite significant decrease in degree of liver stiffness and Child score, there was not any significant difference between 2 groups (P= 0.982 & 0.611 respectively).

while atorvastatin is efficacious in improvement of liver fibrosis and function among cryptogenic cirrhotics, adding aspirin is unable to potentiate its positive effects although this issue worth to further be clarified in future studies.